Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel ultrasensitive assay for plasma p-tau217: performance in individuals with subjective cognitive decline and early Alzheimer's disease.
Gonzalez-Ortiz F, Ferreira PCL, Gonzalez A, Montoliu-Gaya L, Ortiz-Romero P, Kac PR, Turton M, Kvartsberg H, Ashton NJ, Zetterberg H, Harrison P, Bellaver B, Povala G, Villemagne VL, Pascoal TA, Ganguli M, Cohen AD, Miguillon C, Contador J, Suarez-Calvet M, Karikari TK, Blennow K. Gonzalez-Ortiz F, et al. Among authors: blennow k. medRxiv [Preprint]. 2023 Oct 5:2023.09.26.23296134. doi: 10.1101/2023.09.26.23296134. medRxiv. 2023. Update in: Alzheimers Dement. 2024 Feb;20(2):1239-1249. doi: 10.1002/alz.13525 PMID: 37873312 Free PMC article. Updated. Preprint.
Cerebrospinal fluid levels of fatty acid-binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals.
Dhiman K, Villemagne VL, Fowler C, Bourgeat P, Li QX, Collins S, Rowe CC, Masters CL, Ames D, Blennow K, Zetterberg H, Martins RN, Gupta V. Dhiman K, et al. Among authors: blennow k. Alzheimers Dement (Amst). 2022 Dec 4;14(1):e12377. doi: 10.1002/dad2.12377. eCollection 2022. Alzheimers Dement (Amst). 2022. PMID: 36479019 Free PMC article.
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, Karikari TK, Lantero-Rodriguez J, Brum WS, Lussier FZ, Bezgin G, Stevenson J, Rahmouni N, Kunach P, Wang YT, Fernandez-Arias J, Socualaya KQ, Macedo AC, Ferrari-Souza JP, Ferreira PCL, Bellaver B, Leffa DT, Zimmer ER, Vitali P, Soucy JP, Triana-Baltzer G, Kolb HC, Pascoal TA, Saha-Chaudhuri P, Gauthier S, Zetterberg H, Blennow K, Rosa-Neto P. Therriault J, et al. Among authors: blennow k. JAMA Neurol. 2023 Feb 1;80(2):188-199. doi: 10.1001/jamaneurol.2022.4485. JAMA Neurol. 2023. PMID: 36508198 Free PMC article.
CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
Simrén J, Brum WS, Ashton NJ, Benedet AL, Karikari TK, Kvartsberg H, Sjons E, Lussier FZ, Chamoun M, Stevenson J, Hopewell R, Pallen V, Ye K, Pascoal TA, Zetterberg H, Rosa-Neto P, Blennow K. Simrén J, et al. Among authors: blennow k. Alzheimers Res Ther. 2022 Dec 22;14(1):192. doi: 10.1186/s13195-022-01142-0. Alzheimers Res Ther. 2022. PMID: 36544221 Free PMC article.
Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.
Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, Benussi L, Cantoni V, Saraceno C, Rivolta J, Ashton NJ, Borroni B, Galasko D, Harrison P, Zetterberg H, Blennow K, Karikari TK. Gonzalez-Ortiz F, et al. Among authors: blennow k. Brain. 2023 Mar 1;146(3):1152-1165. doi: 10.1093/brain/awac407. Brain. 2023. PMID: 36572122 Free PMC article.
Plasma biomarker profiles in autosomal dominant Alzheimer's disease.
Johansson C, Thordardottir S, Laffita-Mesa J, Rodriguez-Vieitez E, Zetterberg H, Blennow K, Graff C. Johansson C, et al. Among authors: blennow k. Brain. 2023 Mar 1;146(3):1132-1140. doi: 10.1093/brain/awac399. Brain. 2023. PMID: 36626935 Free PMC article.
Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound.
Meng Y, Goubran M, Rabin JS, McSweeney M, Ottoy J, Pople CB, Huang Y, Storace A, Ozzoude M, Bethune A, Lam B, Swardfager W, Heyn C, Abrahao A, Davidson B, Hamani C, Aubert I, Zetterberg H, Ashton NJ, Karikari TK, Blennow K, Black SE, Hynynen K, Lipsman N. Meng Y, et al. Among authors: blennow k. Brain. 2023 Mar 1;146(3):865-872. doi: 10.1093/brain/awac459. Brain. 2023. PMID: 36694943 Free PMC article.
Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit.
Johnson SC, Suárez-Calvet M, Suridjan I, Minguillón C, Gispert JD, Jonaitis E, Michna A, Carboni M, Bittner T, Rabe C, Kollmorgen G, Zetterberg H, Blennow K. Johnson SC, et al. Among authors: blennow k. Alzheimers Res Ther. 2023 Jan 28;15(1):25. doi: 10.1186/s13195-023-01168-y. Alzheimers Res Ther. 2023. PMID: 36709293 Free PMC article.
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N, Salvadó G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, Ossenkoppele R, Betthauser TJ, Cody KA, Jonaitis EM, Langhough R, Palmqvist S, Blennow K, Janelidze S, Johnson SC, Hansson O. Mattsson-Carlgren N, et al. Among authors: blennow k. JAMA Neurol. 2023 Apr 1;80(4):360-369. doi: 10.1001/jamaneurol.2022.5272. JAMA Neurol. 2023. PMID: 36745413 Free PMC article.
The taxonomy of subjective cognitive decline: proposal and first clinical evidence from the Geneva memory clinic cohort.
Ribaldi F, Palomo R, Altomare D, Scheffler M, Assal F, Ashton NJ, Zetterberg H, Blennow K, Abramowicz M, Garibotto V, Chicherio C, Frisoni GB. Ribaldi F, et al. Among authors: blennow k. Res Sq [Preprint]. 2023 Feb 13:rs.3.rs-2570068. doi: 10.21203/rs.3.rs-2570068/v1. Res Sq. 2023. Update in: Neurodegener Dis. 2024;24(1):16-25. doi: 10.1159/000539053 PMID: 36824709 Free PMC article. Updated. Preprint.
2,197 results